Expert NetworkExpert InterviewLLY

Slingshot members are talking to an expert! The topic is:

Discussing the potential of Lilly's Donanemab based on the Phase 3 TRAILBLAZER-ALZ 2 study after FDA adcomm backs drug

Executed on:Jun 20, 2024 10:40 AM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: UC Health
  • Professor and Endowed Chair of the James J. and Joan A. Gardner Center for Parkinson's Disease at the University of Cincinnati.
  • Treats 150 - 200 patients with Alzheimer’s Disease
  • Research interest includes movement disorders, biomarkers, Parkinson’s disease, and Alzheimer’s disease.

Interview Goal

On this call we will be looking at the Phase 3 TRAILBLAZER-ALZ 2 study results in anticipation of the upcoming FDA PDUFA for Lilly's Donanemab

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.